$1.2001
-0.0299[-2.43%]
At close: Apr 23
$1.2001
0[0.00%]
After Hours: 7:26PM EDT
Aptose Biosciences
(NASDAQ:APTO)Aptose Biosciences Stock (NASDAQ:APTO), Analyst Ratings, Price Targets, Predictions
Aptose Biosciences Inc has a consensus price target of $17.83, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and Piper Sandler on April 3, 2024, March 27, 2024, and February 1, 2024. With an average price target of $11 between Piper Sandler, HC Wainwright & Co., and Piper Sandler, there's an implied 816.59% upside for Aptose Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
RBC Capital
Cantor Fitzgerald
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aptose Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | APTO | Buy Now | Aptose Biosciences | $1.20 | 316.63% | Piper Sandler | Edward Tenthoff | $5 → $5 | Maintains | Overweight | Get Alert |
| 03/27/2024 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1816.51% | HC Wainwright & Co. | Joseph Pantginis | $23 → $23 | Maintains | Buy | Get Alert |
| 02/01/2024 | APTO | Buy Now | Aptose Biosciences | $1.20 | 316.63% | Piper Sandler | Edward Tenthoff | $12 → $5 | Maintains | Overweight | Get Alert |
| 11/10/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1399.88% | RBC Capital | Gregory Renza | $23 → $18 | Maintains | Outperform | Get Alert |
| 09/07/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 3066.4% | Cantor Fitzgerald | Li Watsek | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 899.92% | Piper Sandler | Edward Tenthoff | $37 → $12 | Maintains | Overweight | Get Alert |
| 08/11/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1816.51% | RBC Capital | Gregory Renza | $40 → $23 | Maintains | Outperform | Get Alert |
| 08/11/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1816.51% | HC Wainwright & Co. | Joseph Pantginis | $12 → $23 | Maintains | Buy | Get Alert |
| 08/11/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1149.9% | Oppenheimer | Matthew Biegler | $50 → $15 | Maintains | Outperform | Get Alert |
| 06/12/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 1816.51% | HC Wainwright & Co. | Joseph Pantginis | $12 → $23 | Maintains | Buy | Get Alert |
| 06/12/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 3066.4% | Cantor Fitzgerald | Li Watsek | $6 → $38 | Maintains | Overweight | Get Alert |
| 06/12/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 4066.32% | Oppenheimer | Matthew Biegler | $9 → $50 | Maintains | Outperform | Get Alert |
| 06/07/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 2983.08% | Piper Sandler | Edward Tenthoff | $45 → $37 | Maintains | Overweight | Get Alert |
| 06/07/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 3233.06% | RBC Capital | Gregory Renza | $75 → $40 | Maintains | Outperform | Get Alert |
| 05/09/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 649.94% | Oppenheimer | Matthew Biegler | → $135 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 316.63% | RBC Capital | Gregory Renza | → $75 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 899.92% | HC Wainwright & Co. | Joseph Pantginis | → $180 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 566.61% | Canaccord Genuity | Carey Macrury | $195 → $120 | Maintains | Buy | Get Alert |
| 03/24/2023 | APTO | Buy Now | Aptose Biosciences | $1.20 | 316.63% | RBC Capital | Gregory Renza | → $75 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Aptose Biosciences (APTO)?
The latest price target for Aptose Biosciences (NASDAQ: APTO) was reported by Piper Sandler on April 3, 2024. The analyst firm set a price target for $5.00 expecting APTO to rise to within 12 months (a possible 316.63% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aptose Biosciences (APTO)?
The latest analyst rating for Aptose Biosciences (NASDAQ: APTO) was provided by Piper Sandler, and Aptose Biosciences maintained their overweight rating.
When was the last upgrade for Aptose Biosciences (APTO)?
There is no last upgrade for Aptose Biosciences.
When was the last downgrade for Aptose Biosciences (APTO)?
There is no last downgrade for Aptose Biosciences.
When is the next analyst rating going to be posted or updated for Aptose Biosciences (APTO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Aptose Biosciences (APTO) correct?
While ratings are subjective and will change, the latest Aptose Biosciences (APTO) rating was a maintained with a price target of $5.00 to $5.00. The current price Aptose Biosciences (APTO) is trading at is $1.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.